

DAFTAR PUSTAKA

1. World Health Organization. Global Tuberculosis Report 2021. World Health Organization; 2021. 1–17 p.
2. United Nations. The Sustainable Development Goals Report 2022. 2022. 32 p.
3. Kemenkes. Profil Kesehatan Indonesia 2021. Jakarta: Kementerian Kesehatan RI; 2022. 172–178 p.
4. Dinas Kesehatan Provinsi Jambi. Profil Kesehatan Provinsi Jambi 2020. Jambi: Pemerintah Provinsi Jambi; 2020. 34–35 p.
5. Kemenkes. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK. 01.07/Menkes/755/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis 2019. Kementerian Kesehatan RI; 2019. 28–30 p.
6. Kemenkes. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis. Kementerian Kesehatan RI; 2020. 9–38 p.
7. Sons. Blandy's Urology. 3rd ed. Aboumarzouk OM, editor. Wiley; 2019. 117–120 p.
8. Sales GTM, Foresto RD. Drug-induced nephrotoxicity. Rev Assoc Med Bras. 2020;66(suppl 1):s82–90.
9. Kemenkes. Pedoman Interpretasi Data Klinik. Kementerian Kesehatan RI; 2011. 52–56 p.
10. Al-Naimi M, Rasheed H, Hussien N, Al-Kuraishy H, Al-Gareeb A. Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury. J Adv Pharm Technol Res. 2019;10(3):95.
11. Chang CH, Chen YF, Wu VC, Shu CC, Lee CH, Wang JY, et al. Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population. BMC Infect Dis. 2014 Dec 13;14(1):23.
12. Mustifa, Sugireng. Fungsi Ginjal Penderita Tuberkulosis Paru (TB Paru) Setelah Penggunaan Obat Anti Tuberkulosis Kategori 1 (OAT KAT.1) di Puskesmas Katobu Kabupaten Muna. 2019;3:44–51.
13. PDPI. Tuberkulosis : Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2021. 1–64 p.
14. Kenedyanti E, Sulistyorini L. Analisis Mycobacterium Tuberculosis dan Kondisi Fisik Rumah dengan Kejadian Tuberkulosis Paru. 2021;

15. Dewi Kristini T, Hamidah R. Potensi Penularan Tuberculosis Paru pada Anggota Keluarga Penderita. 2020;15(1):24–7. Available from: <https://jurnal.unimus.ac.id/index.php/jkmi>,
16. Marlinae L, Km S, Kl MH, Syamsul Arifin M, Pd D, Ihya H, et al. Desain Kemandirian Pola Perilaku Kepatuhan Minum Obat Pada Penderita TB Anak Berbasis Android. Yogyakarta: CV Mine; 2019. 3–10 p.
17. Abdulkadir W, Djuwarno N, Rasdianah N, Hiola F. Gambaran Efek Samping Obat Antituberkulosis Pada Pasien Tuberkulosis. Journal Syifa Sciences and Clinical Research [Internet]. 2022;4(1). Available from: <http://ejurnal.ung.ac.id/index.php/jsscr>, E-DOI: <https://doi.org/10.37311/jsscr.v4i1.14220>
18. Dubiwak AD, Gerema U, Abdisa D, Tofik E, Reta W. Amelioration of Nephrotoxicity in Mice Induced by Antituberculosis Drugs Using Ensete ventricosum (Welw.) Cheesman Corm Extract. Int J Nephrol. 2022 Mar 17;2022:1–8.
19. widyastuti rahma, tunjung E, Purwaningsih NV. Modul Pratikum Urinalisis dan Cairan Tubuh. Universitas Muhammadiyah Surabaya; 2018.
20. Alvina, Wiradharma D, Pusparini. Urinalisis Teori dan Pratikum. 1st ed. Vol. 1. Jakarta: Sagung Seto; 2019. 39–41 p.
21. Gandasubrata R. Penuntun Laboratorium Klinik. 7th ed. Jakarta: Dian Rakyat; 1992.
22. Andankar P, Shah K, Patki V. A review of drug-induced renal injury. Journal of Pediatric Critical Care. 2018;5(2):36.
23. Linesiana R, Santoso S dwi, Wijayanti CD. Identifikasi Hasil Makroskopis dan Mikroskopis Urin pada Pasien Tuberkulosis. sainHealth. 2022;6:22–5.
24. Kim SY, Moon AR. Drug-Induced Nephrotoxicity and Its Biomarkers. Biomol Ther (Seoul). 2012 May 31;20(3):268–72.
25. Sakashita K, Murata K, Takahashi Y, Yamamoto M, Oohashi K, Sato Y, et al. A Case Series of Acute Kidney Injury During Anti-tuberculosis Treatment. Internal Medicine. 2019 Feb 15;58(4):521–7.
26. Hati EAP, Wulandari PS, Hanina. Hubungan Lama Konsumsi Obat Anti Tuberkulosis dengan Anemia pada Pasien Tuberkulosis di Puskesmas Kota Jambi. Jambi Medical Journal. 2022;
27. Titus Priyo Harjamto, Holil M Par'i SW. Penilaian status Gizi. Vol. 59. Kementrian Kesehatan RI; 2017.
28. Kristin Doko J, Philomena Erika Rengga M, Ekarista Klau M. Evaluasi Penggunaan Obat Anti Tuberkulosis pada Pasien Baru Tuberkulosis Paru di

Puskesmas Sikumana Tahun 2018. CHMK PHARMACEUTICAL SCIENTIFIC JOURNAL . 2020;3:97–102.

29. Agus Nurjana M. Faktor Resiko Terjadinya Tuberkulosis Paru Usia Produktif (15-49 Tahun) di Indonesia. Media Libangkes. 2015;25(3):163–70.
30. Pratiwi SN, Suryaningsih R. Clinical Description Of Chronic Kidney Disease Patients Hemodializing In Pku Muhammadiyah Hospital Surakarta. 2018;
31. Vaziri ND. Gastrointestinal dysfunction in chronic kidney disease: exploring the role of gut-derived uremic toxins. Journal of renal nutrition. 2012;22(2):210–3.
32. Bare BG. SS. Buku Ajar Keperawatan Medikal Bedah. Jakarta: EGC; 2010. 45–47 p.
33. Farhanisa, Untari EK, Nansy E. KEJADIAN EFEK SAMPING OBAT ANTI TUBERKULOSIS (OAT) KATEGORI 1 PADA PASIEN TB PARU DI UNIT PENGOBATAN PENYAKIT PARU-PARU (UP4) PROVINSI KALIMANTAN BARAT. Jurnal UNTAN. 2015;3(1).
34. Maulitha F, Fitriani N, Rusli R. Analisis Efek Samping Penggunaan Obat Antituberkulosis (OAT) di Instalasi Rawat Jalan RSD BLUD dr. H. Soemarno Sosroatmodjo Tanjung Selor. Proc Mul Pharm Conf. 2022;
35. Sanchez-Alamo B, Cases-Corona C, Fernandez-Juarez G. Facing the Challenge of Drug-Induced Acute Interstitial Nephritis. Nephron. 2023;147(2):78–90.
36. Kusumaningroh D, Susilowati T, Wulandari R. The Correlation of Physical Activity and Treatment Phase with Nutritional Status on Patients Of Lungs Tuberculosis. j ners. 2018;5(1):1–7.
37. Tangkin CP, Mongan AE, Wowor MF. Gambaran protein urin pada pasien tuberkulosis paru dewasa di RSUP Prof.Dr. R. D. Kandou Manado. e-Biomedik (eBm). 2016;4(2):1–7.
38. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008 Sep 15;78(6):743–50.
39. Singh NP, Ganguli A, Prakash A. Drug-induced kidney diseases. J Assoc Physicians India. 2003 Oct;51:970–9.
40. Erlina Wulandari P. Gambaran Proteinuria pada Pasien Tuberkulosis Paru yang Mendapat Terapi Obat Anti Tuberkulosis (OAT) di Puskesmas Kota Palembang Tahun 2022. Poltekkes Palembang. 2022;

41. Kim JS, Kim KJ, Choi EY. Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection. *Medicine*. 2018 Jun;97(22):e10556.
42. Choirunnisa H, Ujiani S, Kusuma H Y. Hubungan Tahapan Mengonsumsi OAT Terhadap Protein Urine Pasien TB paru di Puskesmas Panjang dan Sukaraja Kota Bandar Lampung. 2022;50–4.
43. Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, et al. Feasibility and yield of screening for non-communicable diseases among treated tuberculosis patients in Peru. *The International Journal of Tuberculosis and Lung Disease*. 2018 Jan 1;22(1):86–92.